1. Introduction {#sec1}
===============

Breast cancer has the highest incidence rate and second highest mortality rate among female cancers \[[@B1]\]; thus, its survival prognosis concerns doctors and patients. Prognostic factors are those clinicopathological parameters that are associated with tumor outcomes. In breast cancer, the most used prognostic factors include patient characteristics (age and menstrual status), tumor features (tumor size, node status, and TNM stage), tumor tissue markers (estrogen receptor, progesterone receptor, HER-2 status, and ki-67 status), and genetic markers (BRCA1/2) \[[@B2]--[@B8]\]. Using prognostic factors alone or combined to predict a worse outcome of patients and take advanced treatment early may improve patient survival. Identifying more available and convenient factors is very important.

Serum markers can be easily achieved, and they play an important role in many malignant tumors \[[@B9]--[@B11]\], but their role in breast cancer remains controversial. There is some correlation between tumor markers and tumor clinicopathology \[[@B12]\], and when the acquisition of tissue specimens is not available, in some cases, these markers may offer useful information about the phenotype of the breast cancer at an early stage \[[@B13]\]. Serum tumor markers in breast cancer include cancer antigen 15-3 (CA15-3), cancer antigen 27.29 (CA27.29), carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), circulating extracellular domain of HER-2, and tissue polypeptide-specific antigen (TPS) \[[@B14], [@B15]\]. Among these, CA15-3 and CEA are the most used and recommended markers. The prognostic value of CA15-3 had been approved by some studies \[[@B16]--[@B18]\], while other studies reported negative results \[[@B19]--[@B21]\]. Ebeling et al. in a study of 1046 patients reported CA15-3 in univariate but not in multivariate analysis to be a predictor of a worse outcome \[[@B22]\]. In a review article, Duffy collected at least 10 studies and descriptively indicated that higher CA15-3 may be associated with a poor outcome but did not perform pooled analysis to confirm the results \[[@B14]\]. CEA is less widely investigated as a prognostic factor than CA15-3 because it has a less positive rate and is more controversial. Some studies have reported that CEA is not a predictor in primary and metastasis breast cancer \[[@B20], [@B21], [@B23], [@B24]\], but others have reported that high concentrations of CEA were related to a poor prognosis in breast cancer \[[@B17], [@B25], [@B26]\]. These above contradictory results of CA15-3 and CEA in breast cancer regarding their prognostic value may be due to small sample sizes, variable study designs, or other biases in each single study. We searched and combined available studies in this meta-analysis to explore the prognostic role of CA15-3 and CEA in breast cancer as well as their relationship with tumor clinicopathological factors, hoping to help medical workers affirm and properly use these two serum markers.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

We performed a systematic literature search using PubMed, Embase, and Web of Science. The search strategy terms are as follows: "CA15-3" (e.g., "cancer antigen 15-3," "carbohydrate antigen 15-3," and "cancer associated antigen 15-3"), "CEA" (e.g., "carcinoembryonic antigen," "carcino-embryonic antigen," and "carcino embryonic antigen"), "prognosis" (e.g., "outcome," "survival," "prognostic," "mortality," and "recurrence"), and "breast cancer" (e.g., "breast neoplasms" and "breast carcinoma"). The search was updated to July 15, 2017. The relevant articles were also manually checked.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

The inclusion criteria for this meta-analysis were as follows: (i) the diagnosis of breast cancer was defined based on pathological results, (ii) CEA and CA15-3 were derived from a serum test, (iii) the correlation of serum CEA and/or CA15-3 with overall survival (OS) and/or disease-free survival (DSS) and/or disease-free survival (DFS) and/or progression-free survival (PFS) was reported, and (iv) hazard ratios (HRs) and 95% confidence intervals (CIs) can be directly or indirectly received. The exclusion criteria were as follows: (i) abstracts, letters, reviews, case reports, proficient opinions; (ii) literature not written in English; (iii) studies without hazard ratios (HRs) and 95% CIs; (iv) studies with duplicate data with few cases; and (v) nonhuman studies.

2.3. Data Extraction {#sec2.3}
--------------------

We extracted data by two independent authors and through discussion or consensus with a third author regarding controversial data. The following items were recorded from each study: name of the first author, publication year, country, data inclusion criteria of each study, overall sample size, mean age and follow-up time of patients, tumor data of the TNM stage, time of serum sample collection, cut-off values of CEA and/or CA15-3 and the associated clinicopathological factors, and survival data, including HRs with 95% CIs. We used the Newcastle--Ottawa Scale (NOS) to assess the quality of each study by two authors. The scores included three parts: the selectivity of patients (0--4), comparability of groups (0--2), and assessment of outcome (0--3). Studies with scores \> 5 were considered high quality.

2.4. Statistical Analysis {#sec2.4}
-------------------------

We directly obtained all multivariate data and some univariate data of HRs and 95% CIs from the literature. Few univariate data were estimated according to the methods illustrated by Parmar et al. and Tierney et al. using Engauge 4.0 and an HR calculation spreadsheet \[[@B27], [@B28]\]. HR \> 1 indicated a worse prognosis in breast cancer patients. All the studies with HRs and 95% CI were classified into three groups (studies with primary TNMs I--III to group 1; studies with metastatic breast cancer to group 2; and studies with primary TNMs I--IV or unclear stage into group 3), and the pooled results included all the three study groups. The relationship between CEA and/or CA15-3 with clinicopathological parameters was determined using ORs and 95% CIs.

In this meta-analysis, Cochran\'s *Q* test was undertaken to assess the heterogeneity. All the studies first used fixed-effect (Mantel--Haenszel method) models to calculate the pooled results, but if (heterogeneity *p* value) Ph \< 0.1 or *I* ^2^ \> 50%, which suggested significant heterogeneity, we changed to a more conservative random-effect (DerSimonian--Laird method) model to confirm the results. Subgroup analysis was conducted to explore and explain the heterogeneity. Publication bias was first assessed by Begg\'s funnel plot, and the result of pr \> \|*z*\| \> 0.05 was regarded as no publication bias. If bias was not certain, Egger\'s bias indicator test was used to reconfirm. Results with *p* \< 0.05 were considered statistically significant, and all the results were two sided.

3. Results {#sec3}
==========

3.1. Study Characteristics {#sec3.1}
--------------------------

The initial search information retrieved 751 articles. After careful inspection, 36 studies published between 1986 and 2017 that comprised 12,993 breast cancer patients met our inclusion criteria and were finally included in this meta-analysis \[[@B3], [@B13], [@B16]--[@B21], [@B23]--[@B26], [@B29]--[@B52]\]. The specific processes of the literature selection are shown in [Figure 1](#fig1){ref-type="fig"}. Among them, 18 studies were from Europe and the United States, 14 studies were from Asia, and 4 studies were from Africa. Twenty-eight studies concerned the initial treatment of breast cancer patients, and eight were focused on metastatic breast cancer patients. Twenty-four studies collected serum specimens before treatment, and twelve studies collected serum specimens after surgery or at the time of recurrence and metastases. Thirty-one studies provided the survival information of serum CA15-3, and its cut-off values ranged from 20.11 to 77 U/ml; meanwhile, twenty-three studies provide the survival information of serum CEA, and its cut-off values ranged from 2.5 to 20 ng/ml. Clinicopathology information correlated with serum CA15-3 or CEA could be extracted from sixteen studies. Further information of articles in this study is shown in [Table 1](#tab1){ref-type="table"}.

3.2. CA15-3 and DFS in Breast Cancer {#sec3.2}
------------------------------------

Fourteen studies provided univariate HRs and 95% CIs of DFS according to the cut-off value of serum CA15-3 ([Figure 2(a)](#fig2){ref-type="fig"}). Combined data from the fourteen studies showed that higher CA15-3 was significantly corrected with poor DFS with a pooled univariate HR of 2.61 (95% CI: 2.17--3.13) with significant heterogeneity (*I* ^2^ = 50%, Ph = 0.02, random effects model). Ten studies provided multivariate HR and 95% CI information of DFS concerning CA15-3 (HR = 1.56, 95% CI: 1.38--1.76, *I* ^2^ = 31%, Ph = 0.16, fixed-effect model; [Figure 3(a)](#fig3){ref-type="fig"}). Only one study was included in group 2, and it showed that CA15-3 was not an independent prediction factor for DFS in metastatic breast cancer (group 2: HR = 1.28; 95% CI 0.43--3.80; *p* = 0.65). Among the fourteen studies, two studies reported the results of PFS that was the result of group 2, which showed that HR was 2.00 (95% CI: 1.46--2.74) for PFS without significant heterogeneity (*I* ^2^ = 0%, Ph = 0.69). In multivariate subgroup analysis, the results in European countries and the United States, compared with those in Asian and African countries, showed significant subgroup heterogeneity and lower cut-off values in pretreatment patients had higher prognostic values ([Table 2](#tab2){ref-type="table"}).

3.3. CA15-3 and OS in Breast Cancer {#sec3.3}
-----------------------------------

Twenty-one studies had extractable univariate OS HR data concerning CA15-3 ([Figure 2(b)](#fig2){ref-type="fig"}). Elevated CA15-3 indicated a shorter OS (HR = 2.86, 95% CI: 2.31--3.54, *p* \< 0.001) with obvious heterogeneity (*I* ^2^ = 72%, Ph \< 0.001, random-effect model). Heterogeneity was significantly different among the three groups as the pooled HR was the lowest in group 2 (group 1: HR = 2.95, 95% CI 2.28--3.82, *I* ^2^ = 22%, Ph = 0.26; group 2: HR = 1.79, 95% CI 1.51--2.12, *I* ^2^ = 0%, Ph = 0.66; group 3: HR = 3.87, 95% CI 2.74--5.46, *I* ^2^ = 74%, Ph = 0.0003). Stratification by ethnicity found that CA15-3 was a negative predictor for OS in both European countries and the United States (HR = 2.35, 95% CI: 1.74--3.18, *p* \< 0.001) and in Asian and African countries (HR = 3.50, 95% CI: 2.59--4.71, *p* \< 0.001). Fifteen studies reported multivariate data of OS ([Figure 3(b)](#fig3){ref-type="fig"}). Elevated CA15-3 was an independent prognosis predictor for OS in breast cancer with a merged HR of 2.03 (95% CI: 1.76--2.33, *p* \< 0.001), and heterogeneity was not significant (*I* ^2^ = 0%, Ph = 0.45). Among these three groups, no significant heterogeneity was seen. The subgroup analysis results are shown in [Table 2](#tab2){ref-type="table"}.

3.4. CEA and DFS in Breast Cancer {#sec3.4}
---------------------------------

The univariate HR of ten studies and multivariate HR of nine studies of CEA and DFS could be obtained. Pooled univariate data showed that high CEA was associated with worse DFS with HR = 2.60 (95% CI: 2.23--3.04; no significant heterogeneity *I* ^2^ = 0%, Ph = 0.91, fixed-effect model; [Figure 2(c)](#fig2){ref-type="fig"}). The meta-analysis of multivariate data indicated that CEA was an independent predictor for DFS with a HR of 1.77 and the 95% CI ranging from 1.53 to 2.04 (no significant heterogeneity *I* ^2^ = 0%, Ph = 0.82, fixed-effect model; [Figure 3(c)](#fig3){ref-type="fig"}). There was no heterogeneity among the three groups in either univariate or multivariate analysis.

3.5. CEA and OS in Breast Cancer {#sec3.5}
--------------------------------

Meta-analysis of sixteen univariate HR results showed that breast cancer patients with higher CEA levels were significantly associated with shorter OS (HR = 2.46, 95% CI: 1.93--3.15, *p* \< 0.001; heterogeneity: *I* ^2^ = 70%, Ph \< 0.001; random-effect model; [Figure 2(d)](#fig2){ref-type="fig"}). Classification according to the three groups can partly explain the heterogeneity of the pooled results as each group showed no significant heterogeneity but subgroup heterogeneity differences were significant (group 1: HR = 3.68, 95% CI 2.65--5.09, *I* ^2^ = 33%, Ph = 0.17; group 2: HR = 1.52, 95% CI 1.27--1.82, *I* ^2^ = 0%, Ph = 0.41; group 3: HR = 2.61, 95% CI 1.88--3.62, *I* ^2^ = 42%, Ph = 0.14). Pooled multivariate HR results also provided similar results as higher CEA revealed an HR of 1.72 (95% CI: 1.49--1.99) in OS without significant heterogeneity ([Figure 3(d)](#fig3){ref-type="fig"}). We performed subgroup analysis and found that, in univariate analysis, CEA derived from primary breast cancer had a higher HR than that from metastatic breast cancer. Subgroup analysis was also performed according to different cut-off values, ethnicity, and publication year ([Table 2](#tab2){ref-type="table"}).

3.6. CA15-3 and CEA with Tumor Clinicopathological Parameters {#sec3.6}
-------------------------------------------------------------

We extracted twelve factor data according to the cut-off of the high and low groups of CA15-3 or CEA ([Table 3](#tab3){ref-type="table"}). The results demonstrated that patients aged ≤35 years had a higher rate of CA15-3 increase (OR = 1.83, 95% CI: 1.20--2.80, *p* = 0.05), while younger ages had a lower rate of CEA rise (OR = 0.52, 95% CI: 0.29--0.94, *p* = 0.03). Higher rate of CA15-3 and CEA rise were correlated with tumor burden as larger tumor size, lymph node metastasis, and advanced TNM stages. Higher CA15-3 rates were also related to an advanced tumor histological grade (OR = 0.63, 95% CI: 0.46--0.87, *p* = 0.005). However, non-triple-negative-type breast cancer was more likely to associated with a CEA level increase (OR = 2.08, 95% CI: 1.30--3.33, *p* = 0.003).

3.7. Publication Bias {#sec3.7}
---------------------

Begg\'s funnel plot was used to evaluate publication bias. All the results except one showed no significant publication bias as the values of pr \> \|*z*\| \> 0.05. The multivariate pooled results of OS in CA15-3 had pr \> \|*z*\| = 0.01 for Begg\'s test. Next, we carefully examined Begg\'s funnel plot and performed Egger\'s test for this result. Egger\'s test showed *p* \> \|*t*\| = 0.104, and Begg\'s funnel plot was approximately symmetrical; thus, we believe that publication bias did not show a significant difference (Supplement [Figure 1](#supplementary-material-1){ref-type="supplementary-material"}).

4. Discussion {#sec4}
=============

The prognostic factors of breast cancer include tumor biopathological factors such as tumor burden, hormone receptors, HER-2, and Ki-67 levels \[[@B53], [@B54]\]. All these factors should be determined directly from tumor tissue through biopsy or surgery. It would be desirable if serum markers were used as available factors for prognosis. At present, the use of serum tumor markers in breast cancer is less well established because of its lower sensitivity and specification. Many studies have reported a low positive rate of CA15-3 and an even lower rate of CEA \[[@B17], [@B34]\]. Without more powerful serum markers, although imperfect, CA15-3 and CEA remain the most commonly used biomarkers in breast cancer and are recommended for practical use by the American Society of Clinical Oncology (ASCO). However, because of insufficient data, the use of CA15-3 and CEA as screening, diagnostic, and staging tests to detect recurrence and monitoring the response to treatment alone is not recommended by ASCO as well as its prognostic functions \[[@B15]\]. However, the European Group on Tumor Markers has recommended the use of CEA and CA15-3 to assess the prognosis in breast cancer \[[@B55]\]. Our meta-analysis was focused on serum CA15-3 and CEA prognostic ability and their best use of these two markers in breast cancer.

The meta-analysis indicated that an elevated CA15-3 level significantly corresponded with poor DFS and OS of breast cancer. In our analysis, serum CA15-3 had prognostic ability in the pretreatment of primary early-stage and primary all-stage breast cancer patients. It also showed prognostic values in metastasis in OS but not in multivariate analysis of DFS because of only one study reported this result, and it may show great bias. The reason why CA15-3 can predict the prognosis in breast cancer is not fully clear, but as CA15-3 is the soluble form of MUC1, this may be related with the function of MUC1. MUC1 was reported to not only allow the cancer cells to escape the immune system but also promote cancer cell migration by activating some membrane receptors \[[@B56]--[@B59]\]. Serum CA15-3 in metastasis studies had lower HR than that in primary studies. The cause may be that CA15-3 is closely corrected with tumor burden, and in pretreated tumors, it is consistently associated with tumor characteristics that can best predict the prognosis of survival \[[@B60]\]. Nieder et al. found that overall survival was significantly associated with CA15-3 in brain metastasis patients with breast cancer and this trend was not found in other cancers \[[@B32]\]. Subgroup analysis indicated that different cut-off values of pretreatment tumor studies had different predictive abilities, and the lower cut-off value studies had higher HRs in DFS and OS. However, Keshaviah et al. combined 7 study group trials and found a lower cut-off would decrease the predictive value of CA15-3 \[[@B61]\]. This different result may be because Keshaviah used serum CA15-3 tested at any time during disease; however, in the present study, we used the pretreatment serum sample only. We also found differences according to country. European countries and the United States had lower HRs than Asian and African countries because developed countries had improved screening methods and self-consciousness. As the tumor can be found at an early stage in developed countries \[[@B62]--[@B64]\], CA15-3, used as a predictor, may be more useful in developing countries, and this region-specific use of tumor marker test phenomenon was also found by Ramsey et al. \[[@B65]\]. Though CA15-3 seems to be able to assess the prognosis of breast cancer, there was lack of prospective testing to clarify it which limited its practical use in the clinical setting.

The CEA levels are less likely to be elevated than CA15-3; however, in symptomatic breast cancer patients, CEA sensitivity increased, and some studies found that CEA are able to correlate with the stage of disease as well as prognosis though these results are also in dispute. De Jong-Bakker et al. reported the pretreatment level of CEA had no relationship with all groups of patients regarding prognosis as the same results of other small-sample studies report \[[@B33], [@B34], [@B44], [@B66]\]. However, in our pooled results, higher serum CEA had lower DFS and OS both in univariate and multivariate analyses. Serum CEA showed no significant difference in HR in primary and metastasis breast cancer regarding DFS but had a higher HR of primary cancer than metastasis regarding OS. Subgroup analysis showed a lower cut-off value, and studies in Asian and African countries had higher HRs with the same tendency as CA15-3. In clinical use, CEA can be informative when levels of CA15-3 remain below the cut-off point, but for now, no high-level evidence study has verified it \[[@B67]\].

CA15-3 and CEA have been reported to be associated with clinicopathological parameters \[[@B68]\]. Both the CA15-3 and CEA levels were elevated with a larger tumor size, positive lymph node metastasis, and advanced TNM stage. A higher elevation of the markers does not indicate that their prognostic value has increased. In CA15-3 and CEA with tumor burden prognostic analysis, Molina et al. found that CEA had prognostic values in node-positive or node-negative breast cancer, but CA15-3 showed a prognostic value only in the node-negative patients \[[@B47]\]. Gion et al. also found that CA15-3 was significantly associated with the prognosis in node-positive cases not in node-negative cases \[[@B69]\]. In patients younger than 35 years and older, the results in CA15-3 and CEA had significant differences and were reversed. Young patients are more likely to have elevated CA15-3; however, older patients are more likely to have elevated CEA. This can inspire doctors to use different cut-off values in young and older breast cancer patients to best manage young patients. The molecular types of breast cancer may also be different in tumor markers expressed. Triple-negative breast cancer may more likely show high CEA according to a study that included 247 triple-negative breast cancer patients, in which the best cut-off value using the X-Tile program was 6 ng/ml higher than the recommended 5 ng/ml \[[@B25]\]. Li et al.\'s study and other studies found that the CA15-3 levels showed a significant difference according to molecular subtype \[[@B60], [@B70]\], but the pooled results of our study saw no difference.

Several limitations need to be carefully considered in this analysis. First, almost all the included studies in this analysis were retrospective, making them more susceptible to some biases. Though we could not exclude all potential residual confounding, the asymmetry in the funnel plots at least showed the absence of publication bias, thus maintaining the substantial consistency of the results. Second, the publication year of the included studies in this analysis ranged from 1986 to 2017. This long period led to great differences; thus, we performed subgroup analysis and used the cut-off year of 2010 to limit the heterogeneity. Third, some studies have found that CA15-3 and/or CEA only had prognostic value according to molecular tumor types, but we could not identify sufficient studies to pool the results according to different molecular types of breast cancer. Fourth, although we performed multivariate analysis of CA15-3 and CEA as prognostic factors, the multivariate analyses were adjusted to different factors in different studies; thus, the pooled results using CA15-3 and/or CEA as an independent predictor should be carefully considered.

In conclusion, we found that both CA15-3 and CEA were good prognostic factors for poor DFS and OS when abnormal levels were found in breast cancer patients. Furthermore, higher CA15-3 or CEA had more significant prognostic significance for pretreatment primary breast cancer, a cancer occurring in Asian and African countries. Elevated CA15-3 and CEA were closely associated with age and tumor burden. In the future, more studies with uniform cut-off values, large-scale data, and good designs are needed to validate our conclusion.
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###### 

Figure 1: Begg\'s funnel plot of the study: (a) univariate result of DFS of CA15-3; (b) multivariate result of DFS of CA15-3; (c) univariate result of OS of CA15-3; (d) multivariate result of OS of CA15-3; (e) univariate result of DFS of CEA; (f) multivariate result of DFS of CEA; (g) univariate result of OS of CEA; (h) multivariate result of OS of CEA.

###### 

Click here for additional data file.

![Flow chart of the included studies.](DM2018-9863092.001){#fig1}

![Meta-analysis of the univariate result associations between CA15-3/CEA and OS/DFS of breast cancer. The results are presented as an individual and pooled HR and 95% CI: (a) DFS of CA15-3; (b) OS of CA15-3; (c) DFS of CEA; (d) OS of CEA.](DM2018-9863092.002){#fig2}

![Meta-analysis of the multivariate result associations between CA15-3/CEA and OS/DFS of breast cancer. The results are presented as an individual and pooled HR and 95% CI: (a) DFS of CA15-3; (b) OS of CA15-3; (c) DFS of CEA; (d) OS of CEA.](DM2018-9863092.003){#fig3}

###### 

Main characteristics of all the studies included in the meta-analysis.

  Study         Year   Study region   Study continent   Tumor type                                                        Sample size   Follow-up time mean (months)   Patients average age (years)   Serum sample collected time                                                                                  Stage         CA15-3 cut-off value (U/ml)   Outcome    CEA cut-off value (ng/ml)   Outcome   Whether had association of clinicopathological characteristics with CA15-3 or CEA   NOS score
  ------------- ------ -------------- ----------------- ----------------------------------------------------------------- ------------- ------------------------------ ------------------------------ ------------------------------------------------------------------------------------------------------------ ------------- ----------------------------- ---------- --------------------------- --------- ----------------------------------------------------------------------------------- -----------
  Albuquerque   1995   UK             Europe            Metastatic breast cancers                                         85            N                              60.52                          Pretreatment                                                                                                 M             40                            OS         4                           OS        No                                                                                  6
  Berruti       1994   Italy          Europe            Advanced breast cancer                                            115           35                             56                             At first recurrence of disease before the start of any endocrine or cytotoxic therapy                        M             30                            OS         N                           N         No                                                                                  5
  Canizares     2001   Spain          Europe            Primary early breast cancer                                       364           72                             56                             Pretreatment                                                                                                 I, II, III    40                            DFS, OS    6                           DFS, OS   No                                                                                  7
  Chen          2015   China          Asia              Breast cancer with positive lymph nodes                           220           36                             49.0                           Pretreatment                                                                                                 II, III, IV   28                            OS         N                           N         No                                                                                  7
  Dai           2016   China          Asia              Triple-negative breast cancer                                     247           120                            46.8                           Pretreatment                                                                                                 I--IV         21.8                          DFS, OS    6.0                         DFS, OS   Yes                                                                                 7
  Darlix        2016   France         Europe            Metastatic breast cancers                                         250           40.8                           58.4                           Not pretreatment                                                                                             M             30                            OS         N                           N         No                                                                                  6
  Di Gioia      2015   Germany        Europe            Early-stage breast cancer                                         241           41.5                           57                             Pretreatment                                                                                                 I, II, III    24                            DFS, CSS   N                           N         Yes                                                                                 7
  Duffy         2004   UK             Europe            Breast cancer                                                     600           75.24                          N                              Pretreatment                                                                                                 Not clear     30                            OS         N                           N         Yes                                                                                 7
  Elfagieh      2012   Libya          Africa            29 had locoregional breast cancer and 21 advanced breast cancer   50            28                             N                              Not clear                                                                                                    I--IV         35.57                         OS         8.82                        OS        Yes                                                                                 6
  Giovanella    2002   Italy          Europe            Primary breast cancer                                             212           26                             53.6                           Pretreatment                                                                                                 I--IV         30                            OS         5                           OS        No                                                                                  7
  Hewala        2013   Egypt          Africa            Stages II and III breast cancer                                   100           50                             48.36                          Pretreatment                                                                                                 II, III                                     N          4.88                        DFS       No                                                                                  8
  James         2003   UK             Europe            Bone metastasis breast cancer                                     213           N                              N                              After metastasis                                                                                             M             35                            OS         10                          OS        No                                                                                  7
  Kacan         2016   Turkey         Europe            Early-stage breast cancer                                         448           50                             51                             Pretreatment                                                                                                 I, II, III    31.3                          DFS, OS    5                           DFS, OS   No                                                                                  8
  Kumpulainen   2002   Finland        Europe            Primary breast cancer                                             272           124.8                          54                             In most patients, CA15-3 was assessed pre-first treatment; in the minority, by 4 weeks after the operation   0--IV         30                            OS         N                           N         Yes                                                                                 7
  Lee           2013   Korea          Asia              Metastatic breast cancers                                         349           18                                                            At recurrence                                                                                                M             20.11                         OS         3.88                        OS        Yes                                                                                 6
  Loprinzi      1986   South Africa   Africa            Metastatic breast cancers                                         97            N                              N                              After recurrence                                                                                             M             N                             N          5                           OS        Yes                                                                                 6
  Martin        2006   Spain          Europe            Primary early breast cancer                                       818           43                             59                             Pretreatment                                                                                                 I, II, III    30                            DFS        N                           N         Yes                                                                                 7
  Molina        1998   Spain          Europe            Primary breast cancer                                             413           N                              N                              Pretreatment                                                                                                 I--IV         35                            DFS        5.0                         DFS       No                                                                                  5
  Molina        2010   Spain          Europe            Primary breast cancer                                             2062          N                              N                              Pretreatment                                                                                                 I--IV         30                            DFS, OS    5                           DFS, OS   Yes                                                                                 8
  Nakamura      2017   Japan          Asia              Primary breast cancer                                             208           93.6                           55.3                           Not clear                                                                                                    0--IV         27                            OS         5                           OS        No                                                                                  7
  Nan           2017   China          Asia              Primary breast cancer                                             46            27                             60                             Pretreatment                                                                                                 Not clear     N                             N          2.885                       OS        No                                                                                  5
  Nieder        2015   Norway         Europe            Breast cancer with brain metastases                               14            13.8                                                          Before recurrence                                                                                            M             77                            OS         N                           N         No                                                                                  5
  Nishimiya     2014   Japan          Asia              Primary breast cancer                                             247           120                            51.7                           Pretreatment                                                                                                 I, II, III    28                            DFS, OS    2.5                         DFS, OS   No                                                                                  8
  Nisman        2013   Israel         Asia              Primary early breast cancer                                       159           76                             N                              Pretreatment                                                                                                 I, II, III    30.0                          DFS        N                           N         Yes                                                                                 6
  Park          2008   Korea          Asia              Early-stage breast cancer                                         740           37.2                           47                             Pretreatment                                                                                                 I, II, III    20.11                         DFS, OS    3.88                        DFS, OS   Yes                                                                                 8
  Pierga        2012   France         Europe            Metastatic breast cancers                                         84            14.9                           57                             After recurrence                                                                                             M             N                             N          N                           PFS       No                                                                                  6
  Rasmy         2016   Egypt          Africa            Early-stage breast cancer                                         280           33.18                          49                             Pretreatment                                                                                                 I, II, III    25                            DFS, OS    N                           N         Yes                                                                                 7
  Richard       1988   USA            America           Stage II and III breast cancer                                    529           72                             N                              Pretreatment                                                                                                 II, III       N                             N          20                          DFS, OS   Yes                                                                                 8
  Shao          2015   China          Asia              Early-stage breast cancer                                         432           N                              50                             Pretreatment                                                                                                 I, II, III    25                            DFS, OS    5.0                         DFS, OS   Yes                                                                                 8
  Shering       1998   Ireland        Europe            Operable breast cancer                                            368           39.36                          56                             Pretreatment                                                                                                 I, II, III    30                            DFS, OS    N                           N         No                                                                                  7
  Turanli       2010   Turkey         Europe            Isolated bone metastasis breast cancer                            129           38                             51                             After bone metastasis                                                                                        M             30                            PFS, OS    N                           N         Yes                                                                                 7
  Uehara        2008   Japan          Asia              Primary breast cancer                                             1663          N                              N                              Pretreatment                                                                                                 I--IV         28                            DFS, OS    5.0                         DFS, OS   No                                                                                  7
  Velaiutham    2008   Malaysia       Asia              Primary breast cancer                                             322           N                              N                              Pretreatment                                                                                                 I--IV         50                            OS         N                           N         No                                                                                  5
  Wang          2014   China          Asia              Breast cancer                                                     86            N                              N                              Not clear                                                                                                    Not clear     25.00                         OS         3.40                        OS        No                                                                                  5
  Wu            2014   China          Asia              Early-stage breast cancer                                         470           49.9                           48                             Pretreatment                                                                                                 I, II, III    25                            DFS, OS    5.0                         DFS, OS   Yes                                                                                 7
  Zhao          2011   China          Asia              Stage IV breast cancer with bone metastases                       60            31.4                           48.5                           Pretreatment                                                                                                 M             25                            PFS        10                          PFS       No                                                                                  8

OS: overall survival; PFS: progress-free survival; DFS: disease-free survival; M: metastasis; N: not available; NOS: Newcastle--Ottawa Scale.

###### 

Summary of the meta-analysis results.

  Analysis                                             Univariate analysis   Multivariate analysis                                                                       
  ---------------------------------------------------- --------------------- ----------------------- --------- ----- ---------- ---- ------------------- --------- ----- ------
  CA15-3 DFS                                                                                                                                                             
   All                                                 14                    2.61 (2.17--3.13)       \<0.001   50    0.02       10   1.56 (1.38--1.76)   \<0.001   31    0.16
   Subgroup 1                                                                                                                                                            
    Primary early-stage breast cancer                  9                     2.57 (2.14--3.08)       \<0.001   21    0.25       7    1.80 (1.53--2.11)   \<0.001   0     0.63
    Metastatic breast cancer                           2                     2.00 (1.46--2.74)       \<0.001   0     0.69       1    1.28 (0.43--3.80)   0.65      ---   ---
    Primary all-stage or unclear-stage breast cancer   3                     2.88 (1.54--5.41)       \<0.001   82    0.004      2    1.28 (1.06--1.55)   \<0.001   40    0.20
   Subgroup 2                                                                                                                                                            
    Cut-off ≤ 25                                       6                     2.84 (2.30--3.50)       \<0.001   0     0.77       5    1.80 (1.50--2.16)   \<0.001   0     0.85
    Cut-off \> 25                                      6                     2.69 (1.87--3.87)       \<0.001   75    0.001      4    1.39 (1.17--1.64)   \<0.001   59    0.06
   Subgroup 3                                                                                                                                                            
    Asia and Africa                                    8                     3.18 (2.46--4.11)       \<0.001   44    0.08       6    1.96 (1.57--2.44)   \<0.001   0     0.65
    Europe and America                                 6                     2.14 (1.82--2.52)       \<0.001   0     0.67       4    1.41 (1.22--1.63)   \<0.001   24    0.27
   Subgroup 4                                                                                                                                                            
    Sample size \< 500                                 11                    2.37 (2.00--2.81)       \<0.001   20    0.26       7    1.78 (1.50--2.10)   \<0.001   0     0.65
    Sample size ≥ 500                                  3                     3.36 (2.01--5.61)       \<0.001   79    0.008      3    1.35 (1.13--1.61)   0.001     50    0.14
   Subgroup 5                                                                                                                                                            
    Publish year \> 2010                               7                     2.82 (2.3--3.48)        \<0.001   0     0.45       6    1.80 (1.50--2.17)   \<0.001   0     0.53
    Publish year ≤ 2010                                7                     2.45 (1.86--3.23)       \<0.001   69    0.004      4    1.39 (1.19--1.64)   \<0.001   39    0.18
  CA15-3 OS                                                                                                                                                              
   All                                                 21                    2.86 (2.31--3.54)       \<0.001   72    \<0.0001   15   2.03 (1.76--2.33)   \<0.001   0     0.45
   Subgroup 1                                                                                                                                                            
    Primary early-stage breast cancer                  7                     2.95 (2.28--3.82)       \<0.001   22    0.26       6    1.93 (1.46--2.55)   \<0.001   0     0.84
    Metastatic breast cancer                           6                     1.79 (1.51--2.12)       \<0.001   0     0.66       3    1.85 (1.47--2.32)   \<0.001   0     0.78
   Primary all-stage or unclear-stage breast cancer    8                     3.87 (2.74--5.46)       \<0.001   74    \<0.0001   6    2.31 (1.83--2.93)   \<0.001   47    0.09
   Subgroup 2                                                                                                                                                            
    Cut-off ≤ 25                                       5                     3.11 (2.39--4.05)       \<0.001   0     0.59       5    1.98 (1.46--2.69)   \<0.001   0     0.90
    Cut-off \> 25                                      10                    3.57 (2.62--4.88)       \<0.001   74    \<0.0001   7    2.24 (1.79--2.80)   \<0.001   46    0.09
   Subgroup 3                                                                                                                                                            
    Asia and Africa                                    11                    3.50 (2.59--4.71)       \<0.001   70    0.0002     8    1.93 (1.58--2.35)   \<0.001   34    0.16
    Europe and America                                 10                    2.35 (1.74--3.18)       \<0.001   72    0.0002     7    2.13 (1.74--2.60)   \<0.001   0     0.81
   Subgroup 4                                                                                                                                                            
    Sample size \< 500                                 18                    2.87 (2.24--3.7)        \<0.001   75    \<0.0001   12   2.03 (1.74--2.38)   \<0.001   21    0.23
    Sample size ≥ 500                                  3                     2.72 (1.96--3.78)       \<0.001   37    0.20       3    1.99 (1.43--2.77)   \<0.001   0     0.99
   Subgroup 5                                                                                                                                                            
    Publish year \> 2010                               10                    3.17 (2.33--4.31)       \<0.001   62    0.005      8    1.82 (1.52--2.18)   \<0.001   0     0.90
    Publish year ≤ 2010                                11                    2.65 (1.94--3.62)       \<0.001   79    \<0.0001   7    2.41 (1.92--3.03)   \<0.001   21    0.27
  CEA DFS                                                                                                                                                                
   All                                                 10                    2.60 (2.23--3.04)       \<0.001   0     0.91       9    1.77 (1.53--2.04)   \<0.001   0     0.82
   Subgroup 1                                                                                                                                                            
    Primary early-stage breast cancer                  6                     2.80 (2.24--3.52)       \<0.001   0     0.48       5    1.94 (1.56--2.40)   \<0.001   0     0.72
    Metastatic breast cancer                           1                     2.31 (1.26--4.24)       0.007     ---   ---        2    1.91 (1.22--3.00)   0.005     0     0.71
    Primary all-stage or unclear-stage breast cancer   3                     2.45 (1.94--3.09)       \<0.001   0     0.80       2    1.58 (1.28--1.96)   \<0.001   0     0.56
   Subgroup 2                                                                                                                                                            
    Cut-off ≤ 5                                        6                     2.77 (2.29--3.37)       \<0.001   0     0.48       6    1.74 (1.49--2.04)   \<0.001   0     0.54
    Cut-off \> 5                                       3                     2.31 (1.72--3.10)       \<0.001   0     0.98       1    1.84 (1.07--3.16)   \<0.001   ---   ---
   Subgroup 3                                                                                                                                                            
    Asia and Africa                                    6                     2.65 (2.19--3.20)       \<0.001   0     0.46       5    1.95 (1.53--2.48)   \<0.001   0     0.89
    Europe and America                                 4                     2.50 (1.89--3.32)       \<0.001   0     0.80       4    1.67 (1.40--2.00)   \<0.001   0     0.52
   Subgroup 4                                                                                                                                                            
    Sample size \< 500                                 6                     2.62 (2.11--3.24)       \<0.001   0     0.54       7    1.87 (1.54--2.26)   \<0.001   0     0.97
    Sample size ≥ 500                                  4                     2.59 (2.06--3.25)       \<0.001   0     0.64       2    1.65 (1.33--2.05)   \<0.001   59    0.12
   Subgroup 5                                                                                                                                                            
    Publish year \> 2010                               5                     2.79 (2.15--3.60)       \<0.001   0     0.50       7    1.87 (1.54--2.26)   \<0.001   0     0.97
    Publish year ≤ 2010                                5                     2.50 (2.05--3.04)       \<0.001   0     0.74       2    1.65 (1.33--2.05)   \<0.001   59    0.12
  CEA OS                                                                                                                                                                 
   All                                                 16                    2.46 (1.93--3.15)       \<0.001   70    \<0.0001   8    1.72 (1.49--1.99)   \<0.001   0     0.69
   Subgroup 1                                                                                                                                                            
    Primary early-stage breast cancer                  7                     3.68 (2.65--5.09)       \<0.001   33    0.17       4    1.95 (1.49--2.57)   \<0.001   0     0.89
    Metastatic breast cancer                           4                     1.52 (1.27--1.82)       \<0.001   0     0.41       1    1.37 (1.02--1.85)   0.04      ---   ---
    Primary all-stage or unclear-stage breast cancer   5                     2.61 (1.88--3.62)       \<0.001   42    0.14       3    1.79 (1.46--2.20)   \<0.001   0     0.64
   Subgroup 2                                                                                                                                                            
    Cut-off ≤ 5                                        8                     3.80 (2.67--5.39)       \<0.001   59    0.02       6    1.86 (1.56--2.20)   \<0.001   0     0.88
    Cut-off \> 5                                       4                     2.34 (1.73--3.17)       \<0.001   0     0.96       1    1.77 (1.03--3.03)   \<0.001   ---   ---
   Subgroup 3                                                                                                                                                            
    Asia and Africa                                    11                    2.82 (2.07--3.85)       \<0.001   72    \<0.001    7    1.65 (1.38--1.96)   \<0.001   0     0.70
    Europe and America                                 5                     1.87 (1.26--2.77)       0.002     61    0.04       1    1.91 (1.48--2.46)   \<0.001   ---   ---
   Subgroup 4                                                                                                                                                            
    Sample size \< 500                                 13                    2.48 (1.84--3.34)       \<0.001   75    \<0.0001   6    1.64 (1.37--1.95)   \<0.001   0     0.60
    Sample size ≥ 500                                  3                     2.29 (1.75--3.00)       \<0.001   0     0.48       2    1.91 (1.50--2.45)   \<0.001   0     0.96
   Subgroup 5                                                                                                                                                            
    Publish year \> 2010                               9                     3.27 (2.22--4.82)       \<0.001   73    \<0.0001   6    1.64 (1.37--1.95)   \<0.001   0     0.60
    Publish year ≤ 2010                                7                     1.82 (1.39--2.39)       \<0.001   53    0.05       2    1.91 (1.50--2.45)   \<0.001   0     0.96

N: number of studies; HR: hazard ratio; 95% CI: 95% confidence interval; Ph: *p* values of *Q* test for heterogeneity test; OS: overall survival; DFS: disease-free survival; "---" means unavailable.

###### 

Meta-analysis of the association between CEA or CA15-3 and clinicopathological features of breast cancer.

  Variables                                CEA   CA15-3                                                                                                                 
  ---------------------------------------- ----- -------- ------------------- --------- ---- -------- -------- ---- ------ ------------------- --------- ---- --------- --------
  Age (≤35 versus \>35)                    3     1210     0.52 (0.29--0.94)   0.03      10   0.33     Fixed    3    1251   1.83 (1.20--2.80)   0.005     0    0.87      Fixed
  Menopause (no versus yes)                3     792      0.75 (0.33--1.69)   0.49      62   0.07     Random   5    1524   1.16 (0.90--1.50)   0.25      19   0.29      Fixed
  Tumor size (≤5 cm versus \>5 cm)         5     1385     0.28 (0.13--0.57)   \<0.001   69   0.01     Random   9    2766   0.42 (0.29--0.63)   \<0.001   62   0.007     Random
  Lymph node metastasis (no versus yes)    6     3497     0.44 (0.36--0.53)   \<0.001   13   0.33     Fixed    9    4867   0.59 (0.38--0.93)   0.02      84   \<0.001   Random
  TNM stage (I-II versus III-IV)           7     4706     0.39 (0.25--0.60)   \<0.001   77   0.0002   Random   10   5298   0.34 (0.20--0.58)   \<0.001   88   \<0.001   Random
  Histological grade (I-II versus III)     5     2693     0.87 (0.58--1.31)   0.50      53   0.07     Random   8    3980   0.63 (0.46--0.87)   0.005     64   0.006     Random
  ER (no versus yes)                       5     3047     0.75 (0.41--1.38)   0.36      81   0.0003   Random   8    4194   1.23 (0.93--1.61)   0.14      50   0.05      Random
  PR (no versus yes)                       3     2622     0.83 (0.47--1.46)   0.52      78   0.01     Random   7    3810   1.01 (0.86--1.18)   0.95      0    0.91      Fixed
  HER-2 (no versus yes)                    2     730      0.67 (0.25--1.78)   0.42      83   0.01     Random   5    1305   1.11 (0.83--1.47)   0.48      0    0.76      Fixed
  Luminal type (no versus yes)             3     1200     0.72 (0.37--1.39)   0.33      63   0.07     Random   4    1396   1.32 (0.77--2.22)   0.31      65   0.04      Random
  HER-2 overexpress type (no versus yes)   3     1200     0.78 (0.32--1.89)   0.57      67   0.05     Random   4    1396   0.75 (0.50--1.14)   0.18      46   0.13      Fixed
  Triple-negative type (no versus yes)     3     1200     2.08 (1.30--3.33)   0.003     52   0.12     Fixed    4    1396   0.91 (0.65--1.28)   0.59      0    0.51      Fixed

OR: odds ratio; 95% CI: 95% confidence interval; Ph: *p* values of *Q* for heterogeneity test; ER: estrogen receptor; PR: progesterone receptor; HER-2: human epidermal growth factor receptor 2.

[^1]: Academic Editor: Michael Gibson
